NanoViricides Inc
NYSE American:NNVC

  • LAST PRICE
    2.1300
  • TODAY'S CHANGE (%)
    0.0600 (2.8986%)
  • Bid / Lots
    2.1200/ 1
  • Ask / Lots
    2.1300/ 1
  • Open / Previous Close
    2.1100 / 2.0700
  • Day Range
    2.0600
    2.1500
  • 52 Week Range
    1.0000
    2.2900
  • Volume
    165,855

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 8 hours ago by Accesswire
      Companies Mentioned: NNVC

      NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others

      SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model. The animals in only the NV-387 treated group survived completely, as previously reported. The complete survival and clear lungs indicate that NV-387 treatment completely protected the animals and could be potentially a cure for RSV infection.

    • 8 hours ago by Dow Jones
      Companies Mentioned: NNVC

      NV-387, A Broad-Spectrum Antiviral with Strong Activity Against RSV, Influenza A, Coronaviruses, Others

      SHELTON, CT / ACCESSWIRE / May 20, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, says that the strong antiviral activity of NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV infection animal model. The animals in only the NV-387 treated group survived completely, as previously reported. The complete survival and clear lungs indicate that NV-387 treatment completely protected the animals and could be potentially a cure for RSV infection.

  • May 15, 2024

      Show headlines and story abstract

    • 6:31AM ET on Wednesday May 15, 2024 by Accesswire
      Companies Mentioned: NNVC

      NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection

      SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending March 31, 2024 with the Securities and Exchange Commission (SEC) on Tuesday, May 14, 2024. The report can be accessed at the SEC website by searching for the Company's filings.

    • 6:31AM ET on Wednesday May 15, 2024 by Dow Jones
      Companies Mentioned: NNVC

      NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection

      SHELTON, CT / ACCESSWIRE / May 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending March 31, 2024 with the Securities and Exchange Commission (SEC) on Tuesday, May 14, 2024. The report can be accessed at the SEC website by searching for the Company's filings.

  • May 14, 2024

Peers Headlines